5 hours Bayer Reports Positive Safety Data on Parkinson’s Disease Drug Zacks
BAYRY’s experimental Parkinson’s disease drug continues to show a favorable safety profile in all 12 participants in the trial’s high and low-dose cohorts at 24 months.
BAYRY’s experimental Parkinson’s disease drug continues to show a favorable safety profile in all 12 participants in the trial’s high and low-dose cohorts at 24 months.